Storia della carriera di Ofir Moreno
Precedenti posizioni note di Ofir Moreno
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MEI PHARMA, INC. | Direttore Tecnico/Scientifico/R&S | 01/07/2012 | 01/07/2019 |
| Corporate Officer/Principal | 01/07/2019 | 01/07/2022 | |
| DENDREON CORPORATION | Corporate Officer/Principal | 01/08/2003 | 01/11/2007 |
Formazione di Ofir Moreno
| Cornell University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MEI PHARMA, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Ofir Moreno
- Esperienza
